TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19945275
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg i.v.
Study: 16234833
Drug: Supplemented with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemented with high-energy, nutrient dense food from 4 to 7 months of age, twice daily under supervision of field workers.
Study: 10755105
Drug: Dorzolamide 2%
Normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide 2% twice daily added to timolol maleate 0.5% twice daily
Study: 10755105
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate 0.5% twice daily (monotherapy)
Study: 9015696
Drug: Ritodrin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritodrin treatment
Study: 9015696
Drug: Indomethacin treatment
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin treatment (Control)
Study: 8224310
Drug: Antibiotic ointment
Normalized name: CVS Antibiotic Ointment
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic ointment and mydriatic
Study: 8224310
Drug: Antibiotic ointment,
Normalized name: NEOMYCIN SULFATE 3.5 mg in 1 g / BACITRACIN ZINC 400 [iU] in 1 g / POLYMYXIN B SULFATE 5000 [iU] in 1 g TOPICAL OINTMENT [Triple Antibiotic Ointment, Circle K]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic ointment, mydriatic and double eye pad with bandage
Study: 4028870
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g ceftriaxone i.v.
Study: 4028870
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g ceftriaxone i.v.
Study: 4028870
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g ceftriaxone s.c.
Study: 4028870
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g ceftriaxone i.v.
Study: 4028870
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g ceftriaxone s.c. vs 0.5 g ceftriaxone i.v.
Study: 29788156
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with atazanavir/ritonavir plus lamivudine
Study: 29788156
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with atazanavir/ritonavir plus two NRTIs
Study: 23086971
Drug: Atenolol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (25 mg twice daily)
Study: 23086971
Drug: Ivabradine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine (5 mg twice daily)
Study: 18846455
Drug: 60 ml
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 ml of 300 mg I/ml contrast material (CM) in group A
Study: 18846455
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml of 370 mg I/ml contrast material (CM) in group B
Study: 16097363
Drug: Valsartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80 mg/day for 16 weeks)
Study: 16097363
Drug: Felodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (5 mg/day for 16 weeks)
Study: 9829378
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody B72.3 (Group A)
Study: 9829378
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody FO23C5 (Group B)
Study: 2723939
Drug: Tannin-rich carob
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tannin-rich carob pod powder (40% tannins, 1.5 g/kg/day, max 15 g)
Study: 1237822
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg a day)
Study: 23459407
Drug: Losartan/HCTZ combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan/HCTZ combination regimen
Study: 23459407
Drug: High-dose losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose losartan regimen
Study: 21562253
Drug: IVIg (Gamunex®,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg (Gamunex®, Talecris Biotherapeutics) 1 g/kg/day for 2 consecutive days
Study: 19080094
Drug: Nasal administration
Normalized name: Novel Influenza-H1N1-09, live virus for nasal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal administration of fentanyl 0.5 microg/kg
Study: 19080094
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of fentanyl 0.5 microg/kg
Study: 16571956
Drug: Vasopressor infusion
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressor infusion right after SAB (n = 20)
Study: 12771390
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to sulphuric acid concentrations higher than 200 micro g/m(3)
Study: 10999865
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody prophylaxis
Study: 1538151
Drug: Acyclovir (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (30 mg/kg/day at 8‐h intervals)
Study: 1538151
Drug: Vidarabine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vidarabine (10 mg/kg/day as a continuous 12‐h infusion for 7 days)
Study: 29721693
Drug: Nutritional intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional intervention (monthly nutritional guidelines for 9 months)
Study: 25542291
Drug: Hypertensive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertensive group (systolic arterial blood pressure maintained with phenylephrine infusion 20%‐30% over baseline)
Study: 16868545
Drug: Gemcitabine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine administered twice-weekly (40 mg/m²) for 5 weeks concurrent with upper abdominal radiation (50.4 Gy in 5(1/2) weeks) followed by weekly gemcitabine (1000 mg/m²) for two cycles (3 weeks treatment, 1 week off).
Study: 12788887
Drug: Intralipid infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid infusion (24 hours)
Study: 10456487
Drug: Fluvoxamine 50
Normalized name: fluvoxamine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 50 mg per day
Study: 10456487
Drug: Fluvoxamine 100
Normalized name: fluvoxamine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 100 mg per day
Study: 10456487
Drug: Tacrine 40
Normalized name: tacrine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine 40 mg (first study period)
Study: 10456487
Drug: Tacrine 20
Normalized name: tacrine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine 20 mg (second study period)
Study: 8542164
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol (2 x 100 micrograms, four times per day for 7 days)
Study: 8542164
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol (200 micrograms pretreatment)
Study: 1985165
Drug: High-dose chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemoradiotherapy (HD CT/RT) with melphalan 60 mg/m2/d for three doses and total body irradiation (TBI) of either 1.5 Gy (n = 27) or 2.0 Gy (n = 54) twice daily for six doses; 23 patients received additional irradiation of 1.2 Gy twice daily for 10 doses to persisting disease sites; 74 received autologous marrow, 7 allogeneic marrow.
Study: 3878301
Drug: Intravenous aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous aminophylline infusion (180 mg theophylline)
Study: 3878301
Drug: Choline theophyllinate
Normalized name: Choline theophyllinate
DrugBank: Oxtriphylline (DB01303)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Choline theophyllinate administered rectally (400 mg theophylline)
Study: 28749253
Drug: Daily vulvar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vulvar Visnadine spray
Study: 28749253
Drug: On-demand vulvar
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand vulvar Visnadine spray
Study: 27566219
Drug: Iron sulfate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sulfate, 600mg orally daily for 4 weeks
Study: 27566219
Drug: Iron sulfate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sulfate, 600mg orally daily for 4 weeks + rHuEPO, 4000 units subcutaneously, three times a week for 4 weeks
Study: 25172965
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg twice daily for patients ≥70 kg or 0.5 mg once daily for patients <70 kg)
Study: 22448718
Drug: Intravenous oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxycodone (1 mg i.v. boluses, up to 5 mg cumulative dose)
Study: 18443983
Drug: non‐treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: non‐treatment
Study: 9032584
Drug: One-week triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-week triple antimicrobial therapy (bismuth, tinidazole, amoxicillin)
Study: 9032584
Drug: Four-week triple
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-week triple antimicrobial therapy (bismuth, tinidazole, amoxicillin)
Study: 9032584
Drug: One-week triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-week triple antimicrobial therapy
Study: 9032584
Drug: Four-week triple
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-week triple antimicrobial therapy
Study: 1648026
Drug: Intravenous atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous atrial natriuretic peptide (6 pmol/min/kg for 90 minutes)
Study: 20001457
Drug: Thiazide diuretic
Normalized name: Thiazide diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretic (TCTZ)
Study: 16758042
Drug: Erythropoietin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (3 doses of 400 IU/kg per week for 6 weeks)
Study: 16758042
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment aside from conventional medications)
Study: 15252213
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TA) at 2.0 mg/kg up to 80 mg
Study: 15252213
Drug: Triamcinolone hexacetonide
Normalized name: Triamcinolone Hexacetonide
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone hexacetonide (TH) at 1 mg/kg up to 40 mg
Study: 11682374
Drug: Extensive oral
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extensive oral medical information and more personal attention by the surgeon (Group II)
Study: 8645650
Drug: Goserelin depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin depot treatment for 8 weeks before endometrial resection
Study: 27705012
Drug: Anesthesiologist administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesiologist administered propofol sedation
Study: 22103045
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg bid, Clarithromycin 500 mg bid, Amoxycillin 1gr bid for 7 days
Study: 22103045
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg bid, Clarithromycin 500 mg bid, Amoxycillin 1gr bid for 10 days
Study: 22103045
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg bid, Clarithromycin 500 mg bid, Amoxycillin 1gr bid for 14 days
Study: 10696955
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (66 mg iron tablets)
Study: 9491846
Drug: Etoposide: 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide: 200 mg x day x 5 days orally every 3 weeks
Study: 9491846
Drug: Fluorouracil: 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil: 500 mg x m2, Doxorubicin: 50 mg/m2, Cyclophosphamide: 500 mg/m2 intravenously every 3 weeks
Study: 16020262
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol maleate ophthalmic gelling vehicle
Study: 16020262
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol maleate ophthalmic solution
Study: 3302925
Drug: Acetaminophen for
Normalized name: Western Classics Acetaminophen For Child
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen for five days
Study: 27583312
Drug: Enoxaparin/Warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin/Warfarin
Study: 26577962
Drug: Negative Pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative Pressure Wound Therapy (NPWT) using Vacuum Assisted Closure (VAC)
Study: 18162494
Drug: Advanced Moist
Normalized name: Sunmark Advanced Moisturizer Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced Moist Wound Therapy (AMWT)
Study: 23890516
Drug: ezetimibe/simvastatin (10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin (10/20 and 10/40 mg)
Study: 23890516
Drug: atorvastatin (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin (10, 20, 40 mg)
Study: 18184117
Drug: AZD0865 (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0865 (25, 50, or 75 mg/day)
Study: 18184117
Drug: AZD0865 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0865 75 mg/day
Study: 18184117
Drug: AZD0865 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0865 (all doses)
Study: 17009840
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (250 mg, 10 ml)
Study: 17009840
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Pactens) (250 mg, 10 ml)
Study: 619945
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol (80 mg) with metoclopramide
Study: 619945
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol (80 mg) with normal saline
Study: 619945
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol (80 mg) with propantheline
Study: 31433921
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (CABG and medical therapy, medical therapy alone)
Study: 22074851
Drug: Multi-condition collaborative
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-condition collaborative care intervention for disabilities in activities of daily living.
Study: 15574629
Drug: Hydrocortisone, 1
Normalized name: Hydrocortisone, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone, 1 mg/kg per day for 12 days, then 0.5 mg/kg per day for 3 days
Study: 11382656
Drug: Iron-fortified candies
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified candies (30 g/week for 12 weeks, containing 1 mg elemental Fe/g)
Study: 11382656
Drug: Placebo candies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo candies (30 g/week for 12 weeks)
Study: 7924775
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (LPD) - 0.5 g.kg‐1.day‐1 of proteins, 7% calories as protein, 33% as fat, and 60% as carbohydrates
Study: 2894166
Drug: rilmenidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilmenidine (1 mg once daily, doubled to 1 mg twice daily if BP > 90 mm Hg)
Study: 2894166
Drug: methyldopa (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: methyldopa (250 mg twice daily, doubled to 500 mg twice daily if BP > 90 mm Hg)
Study: 23103798
Drug: Posterior tibial
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior tibial nerve stimulation (weekly session for 12 weeks)
Study: 20825792
Drug: Promethazine 12.5
Normalized name: promethazine 12.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 12.5 mg
Study: 18713548
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral calcium carbonate 1500 mg tid and rocaltrol 0.25 microg qn for 12 months)
Study: 17065354
Drug: Glucosamine (500
Normalized name: poly(N-acetyl, N-arginyl)glucosamine (50000-80000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine (500 mg p.o. t.i.d. for 6 weeks)
Study: 1568692
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg slow-release nifedipine (Aprical long 60 mg) administered daily at 1800 hours
Study: 6206207
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment groups (ACOMLA and CHOP-B)
Study: 31286903
Drug: Schroth exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schroth exercise intervention added to standard care (daily home exercises and weekly therapy sessions)
Study: 24044912
Drug: SWL with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SWL with simultaneous inversion therapy (30 head down Trendelenburg position)
Study: 21751891
Drug: Ozone-oxygen treatment
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone-oxygen treatment
Study: 19261730
Drug: 4.4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.4 g/d ALA for 6 weeks
Study: 19261730
Drug: 2.2 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.2 g/d EPA for 6 weeks
Study: 19261730
Drug: 2.3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.3 g/d DHA for 6 weeks
Study: 8101096
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg three times daily and 800 mg in the evening on the day preceding ebastine administration and 400 mg four times daily on the 2 following days)
Study: 3102217
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of monodisperse Teflon particles labelled with 111In, 8.2 micron aerodynamic diameter
Study: 3102217
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of monodisperse Teflon particles labelled with 111In, 11.5 micron aerodynamic diameter
Study: 3102217
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of monodisperse Teflon particles labelled with 111In, 13.7 micron aerodynamic diameter
Study: 3102217
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of monodisperse Teflon particles labelled with 111In, 16.4 micron aerodynamic diameter
Study: 797216
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg doxantrazole
Study: 797216
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg doxantrazole
Study: 797216
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg doxantrazole three times a day for 14 days
Study: 21288326
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2 drugs added to standard treatment
Study: 21288326
Drug: Factorial design
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Factorial design with one‐ to sixteen‐fold the sample size of the combination trial
Study: 9397236
Drug: Randomized controlled
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized controlled trial (RCT) with 10 to 40 mg fosinopril daily
Study: 9397236
Drug: Open label
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label trials with 10 to 40 mg fosinopril daily
Study: 9397236
Drug: Unstructured open
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unstructured open trial of 10 to 40 mg fosinopril daily
Study: 3308719
Drug: imidazole salicylate
Normalized name: imidazole salicylate
DrugBank: Imidazole salicylate (DB13860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: imidazole salicylate (750 mg t.i.d. per os)
Study: 3308719
Drug: ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen (600 mg t.i.d. per os)
Study: 29402521
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg SC every other week plus blinded MTX 2.5 mg PO once weekly for 26 weeks
Study: 29402521
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg SC every other week plus blinded MTX 5 mg PO once weekly for 26 weeks
Study: 29402521
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg SC every other week plus blinded MTX 10 mg PO once weekly for 26 weeks
Study: 29402521
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg SC every other week plus blinded MTX 20 mg PO once weekly for 26 weeks
Study: 27221805
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of fragmented Lactobacillus amylovorus CP1563 daily for 12 weeks
Study: 23101451
Drug: Medical group
Normalized name: ALCOHOL 266.1615 mL in 354.882 mL TOPICAL GEL [Iconic Medical Group Hand Sanitizer - 12oz 12oz]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical group (best medical therapy)
Study: 20038612
Drug: 5FC-CR formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FC-CR formulation 1 (1,500 mg)
Study: 20038612
Drug: 5FC-CR formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FC-CR formulation 2 (1,500 mg)
Study: 20038612
Drug: Immediate-release 5FC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release 5FC product (Ancobon)
Study: 19159590
Drug: KIR2DL1 HLA-C2
Normalized name: Gentamicin C2
DrugBank: Gentamicin C2 (DB17884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KIR2DL1 HLA-C2 combination in UC patients (0.380)